IRIS
TRIPEPI, GIOVANNI LUIGI
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 774
NA - Nord America 487
EU - Europa 313
SA - Sud America 207
AF - Africa 36
OC - Oceania 2
Totale 1.819
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 448
SG - Singapore 282
BR - Brasile 147
IT - Italia 144
CN - Cina 143
VN - Vietnam 135
HK - Hong Kong 59
DE - Germania 32
FR - Francia 29
BD - Bangladesh 24
FI - Finlandia 20
RU - Federazione Russa 20
KR - Corea 19
MX - Messico 18
GB - Regno Unito 17
AR - Argentina 15
EC - Ecuador 15
IN - India 14
ID - Indonesia 12
IQ - Iraq 12
TR - Turchia 11
VE - Venezuela 11
CA - Canada 10
UA - Ucraina 10
ZA - Sudafrica 10
PK - Pakistan 9
NL - Olanda 8
SA - Arabia Saudita 8
PH - Filippine 6
AE - Emirati Arabi Uniti 5
AT - Austria 5
CL - Cile 5
CZ - Repubblica Ceca 5
MA - Marocco 5
PY - Paraguay 5
UZ - Uzbekistan 5
EG - Egitto 4
ET - Etiopia 4
JO - Giordania 4
JP - Giappone 4
KE - Kenya 4
PA - Panama 4
PL - Polonia 4
CO - Colombia 3
NP - Nepal 3
TN - Tunisia 3
AL - Albania 2
BA - Bosnia-Erzegovina 2
BE - Belgio 2
BG - Bulgaria 2
BO - Bolivia 2
DO - Repubblica Dominicana 2
ES - Italia 2
KG - Kirghizistan 2
KZ - Kazakistan 2
LB - Libano 2
MY - Malesia 2
PE - Perù 2
RO - Romania 2
TH - Thailandia 2
TW - Taiwan 2
UY - Uruguay 2
AO - Angola 1
AU - Australia 1
AZ - Azerbaigian 1
BN - Brunei Darussalam 1
BS - Bahamas 1
BY - Bielorussia 1
CH - Svizzera 1
CR - Costa Rica 1
GT - Guatemala 1
HN - Honduras 1
HR - Croazia 1
IE - Irlanda 1
IL - Israele 1
LY - Libia 1
MK - Macedonia 1
MZ - Mozambico 1
NG - Nigeria 1
NI - Nicaragua 1
NZ - Nuova Zelanda 1
OM - Oman 1
PS - Palestinian Territory 1
QA - Qatar 1
RS - Serbia 1
SC - Seychelles 1
SE - Svezia 1
SN - Senegal 1
SY - Repubblica araba siriana 1
Totale 1.819
Salva come PNG Salva come JPEG
Città #
Singapore 116
San Jose 81
Florence 74
Ashburn 63
Hong Kong 58
Boardman 48
Ho Chi Minh City 40
Dallas 32
Beijing 31
Hefei 31
Hanoi 22
Los Angeles 22
Seoul 18
Munich 17
Shanghai 17
Lauterbourg 14
New York 14
São Paulo 13
Helsinki 12
Noto 11
Sesto Fiorentino 11
Santa Clara 10
Washington 10
Da Nang 9
Guayaquil 7
Haiphong 7
Mexico City 7
Orem 7
Turku 7
Brooklyn 6
Portland 6
Quito 6
Biên Hòa 5
Brasília 5
Council Bluffs 5
Montreal 5
Addis Ababa 4
Amsterdam 4
Belo Horizonte 4
Bursa 4
Caracas 4
Chennai 4
Hillsboro 4
Milan 4
Nairobi 4
Ninh Bình 4
Tashkent 4
Thái Nguyên 4
Tokyo 4
Warsaw 4
Amman 3
Baghdad 3
Campinas 3
Caxias do Sul 3
Charlotte 3
Chicago 3
Falkenstein 3
Frankfurt am Main 3
Kyiv 3
Lahore 3
London 3
Phoenix 3
Pretoria 3
Quảng Ngãi 3
Rio de Janeiro 3
Riyadh 3
Rome 3
Vienna 3
Alexandria 2
Angeles City 2
Ankara 2
Atlanta 2
Bangkok 2
Bauru 2
Bishkek 2
Can Tho 2
Casablanca 2
Catania 2
Dhaka 2
Dubai 2
Duhok 2
Feira de Santana 2
Formosa 2
Guangzhou 2
Hải Dương 2
Jeddah 2
Jinhua 2
Juiz de Fora 2
Jundiaí 2
Las Vegas 2
Maldonado 2
Manaus 2
Montes Claros 2
Mosul 2
Mumbai 2
Nuremberg 2
Ogden 2
Olomouc 2
Paris 2
Quận Một 2
Totale 1.021
Salva come PNG Salva come JPEG
Nome #
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients 126
Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trials 123
Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials 116
Genes selection using deep learning and explainable artificial intelligence for chronic lymphocytic leukemia predicting the need and time to therapy 115
Lymphocyte Doubling Time As A Key Prognostic Factor To Predict Time To First Treatment In Early-Stage Chronic Lymphocytic Leukemia 113
Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases 112
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials 112
Spotlight on Melphalan Flufenamide: An Up-and-Coming Therapy for the Treatment of Myeloma 105
Validation of the Alternative International Prognostic Score-E (AIPS-E): Analysis of Binet stage A chronic lymphocytic leukemia patients enrolled into the O-CLL1-GISL protocol 104
Comparison of isatuximab-pomalidomide-dexamethasone versus elotuzumab-pomalidomidedexamethasone in relapsed/refractory multiple myeloma patients: a target trial emulation using real-world data 99
Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study 98
MicroRNA Profiling as a Predictive Indicator for Time to First Treatment in Chronic Lymphocytic Leukemia: Insights from the O-CLL1 Prospective Study 97
Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials 94
The time to first treatment is an independent predictor of overall survival in chronic lymphocytic leukemia 93
TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases 89
Long-term cognitive function changes with non-vitamin K oral anticoagulants in older patients with atrial fibrillation. A multicenter cohort study 81
Prognostic Significance of +1q Alterations in Relapsed/Refractory Multiple Myeloma Treated With Daratumumab‐, Elotuzumab‐, and Carfilzomib‐Based Triplet Regimens: A Multicenter Real‐World Analysis of 635 Patients 75
Clinical Frailty Scale as a Predictor of Early Treatment Discontinuation in Elderly Patients With Chronic Lymphocytic Leukemia Treated With Zanubrutinib: A Multicenter Real‐World Study 34
Skin Carotenoid Score as a Potential Early Biomarker of Metabolic Syndrome Risk in Adolescents 22
Real-World Safety and Effectiveness of Zanubrutinib versus Ibrutinib in CLL: The CLL-ZANU2024 Italian Cohort 21
Relapse Despite MRD Negativity in Multiple Myeloma: Toward Integrated Risk Prediction 14
Totale 1.843
Salva come PNG Salva come JPEG
Categoria #
all - tutte 8.873
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 8.873
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2022/202328 0 0 0 0 0 0 14 0 0 3 11 0
2023/2024239 3 8 52 46 29 32 14 4 4 2 4 41
2024/2025399 9 32 8 25 24 24 8 12 70 41 40 106
2025/20261.177 133 66 83 74 197 98 147 59 127 141 52 0
Totale 1.843